Bavarian Nordic’s monkeypox shot is making it a hot stock again

The biotech firm’s shares are soaring as the monkeypox outbreak continues to spread worldwide.

Photo: Bavarian Nordic / PR

Bavarian Nordic A/S is having a bit of a meme-stock moment, with retail traders buying up shares in the monkeypox vaccine maker as cases of the virus steadily rise.

Shares in the Danish biotech, which makes the only monkeypox vaccine approved by the US Food and Drug Administration (FDA), have gained 69% since hitting a low in early May. At the same time, cases of the virus have jumped from just a handful in Europe at the start of last month to more than 1,200 cases, mostly in men, across the region, as well as in the Americas, the Middle East, and Australia by early June.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs